A Phase III Randomized Study Comparing A Chemotherapy With Cisplatin And Etoposide To A Etoposide Regimen Without Cisplatin For Patients With Extensive Small-Cell Lung Cancer

NCT00658580 Phase 3 COMPLETED

The purpose of this study is to determine if a cisplatin-etoposide regimen improves survival in comparison to a regimen containing etoposide and without platinum derivative.

Details

Lead sponsor	European Lung Cancer Working Party
Phase	Phase 3
Status	COMPLETED
Enrolment	361
Start date	2000-04
Completion	2015-02

Conditions

• Small Cell Lung Carcinoma, Extensive Disease

Interventions

• Cisplatin + etoposide
• Epirubicin + ifosfamide + etoposide

Primary outcomes

• Survival — Survival will be dated from the day of randomisation until death or last follow up

Countries

Belgium, France, Greece, Spain